C. Bascoul-Mollevi

发表

Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells

V. Denis, N. Vié, V. Copois, 2008, Molecular Cancer.

Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality.

P. Mazière, M. Ychou, V. Copois, 2007, Journal of biotechnology.

Two‐part statistics with paired data

C. Bascoul-Mollevi, S. Gourgou-Bourgade, A. Kramar, 2005, Statistics in medicine.

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.

Franck Molina, Andrew Kramar, Pierre Martineau, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Author manuscript, published in "Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2009;50 (12):2033-41"

C. Bascoul-Mollevi, I. Navarro-Teulon, A. Pèlegrin, 2010 .

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review

C. Bascoul-Mollevi, F. Cottone, F. Fiteni, 2019, Quality of Life Research.

Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care

M. Ychou, C. Bascoul-Mollevi, E. Crapez, 2016, Clinical Cancer Research.

Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization

M. Ychou, C. Bascoul-Mollevi, E. Assenat, 2009, BMC Molecular Biology.

Adjuvant Radioimmunotherapy Trial with Iodine-131–Labeled Anti–Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab′)2 after Resection of Liver Metastases from Colorectal Cancer

M. Ychou, P. Rouanet, C. Bascoul-Mollevi, 2008, Clinical Cancer Research.

Validation of an appropriate reference gene for normalization of RT-qPCR data from rectal cancer biopsies

Evelyne, M. Ychou, C. Bascoul-Mollevi, 2009 .

Validation of an appropriate reference gene for normalization of reverse transcription-quantitative polymerase chain reaction data from rectal cancer biopsies.

M. Ychou, C. Bascoul-Mollevi, E. Assenat, 2009, Analytical Biochemistry.

A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy.

C. Bascoul-Mollevi, F. Roquet, I. Navarro-Teulon, 2009, Vaccine.

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies

P. Colombo, C. Bascoul-Mollevi, I. Navarro-Teulon, 2010, The Journal of Nuclear Medicine.

EORTC QLQ-C30 Descriptive Analysis with the qlqc30 Command

C. Bascoul-Mollevi, S. Gourgou-Bourgade, D. Azria, 2015 .

DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy.

C. Bascoul-Mollevi, I. Navarro-Teulon, A. Pèlegrin, 2014, Nuclear medicine and biology.

Prognostic impact of LDH levels in patients with relapsed/refractory seminoma

T. Powles, C. Bascoul-Mollevi, A. Kramar, 2013, Journal of Cancer Research and Clinical Oncology.

Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).

C. Bascoul-Mollevi, J. Bachaud, F. Joly, 2011, International journal of radiation oncology, biology, physics.

Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane.

C. Bascoul-Mollevi, I. Navarro-Teulon, A. Pèlegrin, 2013, Nuclear medicine and biology.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of chromosomal instability on colorectal cancer progression and outcome

I. Soubeyran, C. Bascoul-Mollevi, C. Theillet, 2014, BMC Cancer.

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer

M. Ychou, C. Bascoul-Mollevi, J. Ramos, 2012, PloS one.

Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers

C. Bascoul-Mollevi, E. Crapez, H. Bazin, 2011, The Journal of Biological Chemistry.

A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer

M. Ychou, P. Rouanet, C. Bascoul-Mollevi, 2011, The Pharmacogenomics Journal.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Andrew Kramar, Caroline Bascoul-Mollevi, Christophe Massard, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer.

C. Bascoul-Mollevi, C. Theillet, C. Rodríguez, 2011, The American journal of pathology.

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

T. Powles, C. Bascoul-Mollevi, L. Einhorn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers

Pierre-Marie Martin, Pierre-Jean Lamy, Frédéric Fina, 2011, Breast Cancer Research.

Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons

Manuel Bardiès, André Pèlegrin, Nicolas Chouin, 2008, Radiation research.

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results

B. Chauffert, T. Conroy, C. Bascoul-Mollevi, 2020, Quality of Life Research.

Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women

P. Rouanet, C. Bascoul-Mollevi, J. Solassol, 2009, Clinical Cancer Research.

Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer

P. Rouanet, C. Bascoul-Mollevi, J. Solassol, 2012, Clinical Cancer Research.

Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early‐stage breast cancers

P. Rouanet, C. Bascoul-Mollevi, J. Solassol, 2013, International journal of cancer.

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

P. Auquier, C. Bascoul-Mollevi, C. Borg, 2013, Quality of Life Research.

T. Conroy, C. Bascoul-Mollevi, J. Douillard, 2017, European journal of cancer.

The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer

C. Bascoul-Mollevi, H. Vié, I. Navarro-Teulon, 2014, mAbs.

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

C. Bascoul-Mollevi, B. Robert, A. Pèlegrin, 2012, Neoplasia.

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.

F. Penault-Llorca, C. Bascoul-Mollevi, B. Robert, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

QoLR: An R Package for the Longitudinal Analysis of Health-Related Quality of Life in Oncology

Amélie Anota, Franck Bonnetain, M. Savina, 2017 .

EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer

M. Ychou, P. Rouanet, C. Bascoul-Mollevi, 2011, International journal of cancer.

Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patients

F. Guillemin, T. Conroy, C. Bascoul-Mollevi, 2012, Health and Quality of Life Outcomes.

Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial

C. Lavergne, T. Conroy, C. Bascoul-Mollevi, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study

C. Bascoul-Mollevi, F. Bonnetain, S. Gourgou-Bourgade, 2014, Health and Quality of Life Outcomes.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis.

C. Bascoul-Mollevi, C. Borg, S. Gourgou, 2023, European journal of cancer.

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma

C. Bascoul-Mollevi, J. Solassol, A. Mangé, 2013, International journal of molecular sciences.

Gene expression signature for the prediction of FOLFIRI response in advanced colorectal cancer patients

Caroline, M. Ychou, V. Copois, 2010 .

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice

C. Bascoul-Mollevi, B. Robert, I. Navarro-Teulon, 2011, Breast Cancer Research.

RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis.

M. Ychou, P. Roepman, C. Bascoul-Mollevi, 2014, The Journal of clinical investigation.

EM algorithm estimation of a structural equation model for the longitudinal study of the quality of life

C. Lavergne, C. Bascoul-Mollevi, S. Gourgou, 2018, Statistics in medicine.

RIP 140 increases APC gene expression and controls intestinal homeostasis and tumorigenesis

M. Ychou, C. Bascoul-Mollevi, F. Hollande, 2014 .

Noninternalizing monoclonal antibodies are suitable candidates for I 125 radioimmunotherapy of small-volume peritoneal carcinomatosis

C. Bascoul-Mollevi, I. Navarro-Teulon, A. Pèlegrin, 2011 .

Ann Oncol . Author Manuscript Combined Cetuximab and Trastuzumab Are Superior to Gemcitabine in the Treatment of Human Pancreatic Carcinoma Xenografts

C. Bascoul-Mollevi, B. Robert, I. Navarro-Teulon, 2022 .

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts

C. Bascoul-Mollevi, I. Navarro-Teulon, A. Pèlegrin, 2009 .

Improved long-term expression from helper virus-free HSV-1 vectors packaged using combinations of mutated HSV-1 proteins that include the UL13 protein kinase and specific components of the VP16 transcriptional complex

C. Bascoul-Mollevi, E. Assenat, E. Lopez-Crapez, 2009, BMC Molecular Biology.

Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD

C. Bascoul-Mollevi, Marion Savina, Amélie Anota, 2018, Comput. Methods Programs Biomed..

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Impacts of routine patient-reported-outcomes monitoring in oncology].

C. Bascoul-Mollevi, N. Houédé, F. Fiteni, 2018, Bulletin du cancer.

Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis

C. Bascoul-Mollevi, I. Navarro-Teulon, V. Boudousq, 2009, Journal of Nuclear Medicine.